| Family: | ALPS |
| Name: | ALPS Medical Breakthroughs ETF |
| Inception Date: | 31-Dec-2014 |
| Termination Date: | |
| Investment Objective: | The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the "Underlying Index"). The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States and in the stocks of companies operating in the biotechnology sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the S-Network Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index. |
| Prospectus | |
| Top 10 Holdings | ||
| KYMERA THERAPEUTICS INC | KYMR | 3.9400% |
| ALKERMES PLC | ALKS | 2.9600% |
| CELCUITY INC | CELC | 2.9600% |
| ACADIA PHARMACEUTICALS INC | ACAD | 2.9000% |
| CRINETICS PHARMACEUTICALS IN | CRNX | 2.8300% |
| AMICUS THERAPEUTICS INC | FOLD | 2.8200% |
| STRUCTURE THERAPEUTICS INC | GPCR | 2.7100% |
| APOGEE THERAPEUTICS INC | APGE | 2.6500% |
| MIRUM PHARMACEUTICALS INC | MIRM | 2.6000% |
| VIKING THERAPEUTICS INC | VKTX | 2.5500% |
| Top 10 Holdings Weight: | 28.9% |
| Number of Holdings: | 91 |
| Shares Outstanding: | 2,500,000 |
| Total Net Assets: | 128,050,000 |
| NAV: | 51.13 |
| Net Expense Ratio: | 0.50% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | SMID (Small & Mid) Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
